Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 7, Issue SUPPL. 1, 2007, Pages

  Cohen, Deirdre J ^a   Hochster, Howard S ^a,b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b North East Structural Genomics Center (NESG)   (United States)

Author keywords

Bevacizumab; Capecitabine; Cetuximab; Tyrosine kinase inhibitors; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IMC 1121B; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLACEBO; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VATALANIB; ANGIOGENESIS INHIBITOR; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE; VASCULOTROPIN A;

ACNE; ANTIANGIOGENIC THERAPY; BIOLOGICAL THERAPY; BLEEDING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INFECTION; LUNG EMBOLISM; METASTASIS; MULTIPLE CYCLE TREATMENT; NAIL; NEUROPATHY; NEUTROPENIA; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; THROMBOEMBOLISM; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG EFFECT; METHODOLOGY; PATHOLOGY; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL THERAPY; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; ORGANOPLATINUM COMPOUNDS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 43049167480     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2008.s.004     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
2. Rajpal S, Venook AP. Targeted therapy in colorectal cancer. Clin Adv Hematol Oncol 2006; 4:124-32.
3. Avastin [package insert]. South San Francisco, CA: Genentech Pharmaceuticals; 2007.
4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-6.
5. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841-4.
6. Ishigami SI, Arii S, Furutani M, et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998; 78:1379-84.
7. George ML, Tutton MG, Janssen F, et al. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia 2001; 3:420-7.
8. Yamamori M, Sakaeda T, Nakamura T, et al. Association of VEGF genotype with mRNA level in colorectal adenocarcinomas. Biochem Biophys Res Commun 2004; 325:144-50.
9. Mulay M, Limentani SA, Carroll M, et al. Safety and pharmacokinetics of intravenous VEGF Trap plus FOLFOX4 in a combination phase I clinical trial of patients with advanced solid tumors. J Clin Oncol 2006; 24(18 suppl):606s (Abstract 13061).
10. Rixe O, Verslype C, Meric JB, et al. Safety and pharmacokinetics of intravenous VEGF Trap plus irinotecan, 5-fluorouracil, and leucovorin (I- LV5FU2) in a combination phase I clinical trial of patients with advanced solid tumors. J Clin Oncol 2006; 24(18 suppl):614s (Abstract 13161).
11. Baranda J, Williamson S. The new paradigm in the treatment of colorectal cancer: are we hitting the right target? Expert Opin Investig Drugs 2007; 16:311-24.
12. Matar P, Rojo F, Cassia R, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 2004; 10:6487-501.
13. Sini P, Wyder L, Schnell C, et al. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin Cancer Res 2005; 11:4521-32.
14. Normanno N, Bianco C, De Luca A, et al. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003; 10:1-21.
15. Black JD, Brattain MG, Krishnamurthi SA, et al. ErbB family targeting. Curr Opin Investig Drugs 2003; 4:1451-4.
16. Zhou Y, Li S, Hu YP, et al. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res 2006; 66:404-11.
17. Rychahou PG, Jackson LN, Silva SR, et al. Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann Surg 2006; 243:833-42; discussion 843-4.
18. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
19. Fuchs C, Marshall J, Mitchell E, et al. Updated results of BICC-C study comparing first-line irinotecan/fluoropymidine combinations with or without celecoxib in mCRC: updated efficacy data. J Clin Oncol 2007; 25(18 suppl):170s (Abstract 4027).
20. Sobrero A, Young S, Balcewicz M, et al. Phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in patients with metastatic colorectal cancer: AVIRI. J Clin Oncol 2007; 25(18 suppl):180s (Abstract 4068).
21. Giantonio BJ. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second-and third-line settings. Semin Oncol 2006; 33(5 suppl 10):S15-8.
22. Hochster HS. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer. Semin Oncol 2006; 33(5 suppl 10):S8-14.
23. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/NO16966, a randomized phase III trail in first-line metastatic colorectal cancer. J Clin Oncol 2007; 25(18 suppl):170s (Abstract 4028).
24. Gruenberger T, Tamandl D, Puhalla H, et al. Bevacizumab plus XELOX as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2007; 25(18 suppl):179s (Abstract 4064).
25. Hecht JR, Trarbach T, Jaeger E, et al. A randomized, double-blind, placebo-controlled, phase III study in patients (pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM- 1). J Clin Oncol 2005; 23(16 suppl):2s (Abstract 3).
26. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J Clin Oncol 2007; 25(18 suppl):164s (Abstract 4000).
27. Bokemeyer C, Bondarenko I, Makhson A, et al. Cetuximab plus 5-FU/ FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. J Clin Oncol 2007; 25(18 suppl):172s (Abstract 4035).
28. Venook A, Niedzwiecki D, Hollis D, et al. Phase III study of irinotecan/ 5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J Clin Oncol 2006; 24(18 suppl):148s (Abstract 3509).
29. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007; 25:4557-61.
30. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
31. Ocean AJ, O'Brien K, Lee J, et al. Phase II trial of FOLFOX6, bevaci-zumab and cetuximab in patients with colorectal cancer. J Clin Oncol 2007; 25(18 suppl):182s (Abstract 4075).
32. Meyerhardt J, Stuart K, Fuchs C, et al. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metas-tastic colorectal cancer. Ann Oncol 2007; 18:1185-9.
33. Hecht J, Chidiac T, Mitchell E. An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (Bev) for metastatic colorectal cancer (mCRC). Ann Oncol 2007; 18:vii21 (Abstract 0-0033).
34. Tol J, Koopman M, Rodenburg CJ, et al. Randomised phase III study of capecitabine, oxaliplatin and bevacizumab (CAPOXB) with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim safety analysis. Presented at: the 14th European Cancer Conference; September 23-27, 2007; Barcelona, Spain.